US · Healthcare · Drug Manufacturers - General
EPS came in at 2.04 against a street estimate of 1.59 — a beat of 28.3%.
Analysts rate Bristol-Myers Squibb Company a hold (10 buy, 18 hold, 1 sell out of 29) with an average price target of $64.91.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.40% |
| Vanguard Capital Management, LLC | 6.48% |
| State Street Corp | 4.83% |
| JPMorgan Chase & Co | 4.53% |
| Charles Schwab Investment Management Inc | 2.99% |
| Geode Capital Management, LLC | 2.71% |
| Vanguard Portfolio Management, LLC | 2.26% |
| Bank of America Corp | 1.60% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-30 |
| Results announced · Q3 2026 | 2026-07-30 |
| Shareholder vote results · Q2 2026 | 2026-05-08 |
| Quarterly report · Q1 2026 | 2026-04-30 |
| Results announced · Q2 2026 | 2026-04-30 |
| Proxy statement · Q2 2026 | 2026-03-25 |
| Annual report FY2025 | 2026-02-11 |
| Results announced · Q1 2026 | 2026-02-05 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.63 / share ex-date Jul 2, 2026 · pay Aug 3, 2026 | 2026-07-02 |
| Dividend | $0.63 / share ex-date Apr 2, 2026 · pay May 1, 2026 | 2026-04-02 |
| Dividend | $0.63 / share ex-date Jan 2, 2026 · pay Feb 2, 2026 | 2026-01-02 |
| Dividend | $0.62 / share ex-date Oct 3, 2025 · pay Nov 3, 2025 | 2025-10-03 |
| Dividend | $0.62 / share ex-date Jul 3, 2025 · pay Aug 1, 2025 | 2025-07-03 |
| Announcement | Date |
|---|---|
| Q1 2026 results; reaffirms full-year revenue and EPS guidance Bristol Myers Squibb reported solid Q1 2026 results with total revenues of $11.5 billion, up 3% year-over-year (1% excluding foreign exchange effects). The company's Growth Portfolio drove p | 2026-04-30 |
| 2026 revenue and EPS guidance provided; dividend increased to $0.63 Bristol Myers Squibb reported mixed but encouraging 2025 results with strong momentum in its core Growth Portfolio. Total full-year revenues were $48.2 billion (essentially flat year-over-ye | 2026-02-05 |
| Raising 2025 revenue guidance to $47.5-$48.0 billion range Bristol Myers Squibb reported strong Q3 2025 results with total revenues of $12.2 billion, up 3% year-over-year (2% excluding currency effects). The company's Growth Portfolio—newer drugs dr | 2025-10-30 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bristol-Myers Squibb Company — free to start.
Google PlayApp StoreData updated 2026-08-05.